Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Qlucore Receives European Funding That will Benefit Personalized Medicine

Published: Thursday, September 05, 2013
Last Updated: Thursday, September 05, 2013
Bookmark and Share
Hepatitis C patients to benefit from European funding awarded to Qlucore.

Qlucore has been awarded funding of €0.6 million over a three year period by the European Commission's 7th Framework Programme as part of a €6.0 million consortium project (Grant n° 601851) for the development of mathematical and statistical algorithms focusing on integrating data from multiple analytical platforms focusing on integrating genetic and proteomic data with clinical variables.

On receiving the award, Carl-Johan Ivarsson, CEO, Qlucore said, "Personalized medicine, and in particular Hepatitis C patients, will benefit from the project outcome. One of the primary objectives of the consortium is to provide predictive tests that will lead to improvements in the health of these patients, which will simultaneously reduce the costs of medical treatment."

The consortium, known as the PoC-HCV consortium, aims to develop integrated genetic and protein biomarker tests for use in treating and monitoring HCV patients, as well as in clinical research.

Data and algorithms will be tailored for analysis and treatment in a Point of Care environment for Hepatitis C. One of the outputs from the consortium will be a mobile application prototype where the algorithms are implemented.

Establishing a path for validation and implementation of point-of-care medical devices is a challenge, and the driving vision of the Consortium.

The consortium additionally consists of the coordinator Inserm (Institut Pasteur) (France), Inserm Transfert (France), Epistem (UK) and Biosurfit (Portugal).

With the primary objective to provide Point of Care diagnostic and predictive tests and reduce costs, the approach will capitalize on the consortium's combined expertise spanning leading edge miniaturized molecular testing, lab-on-a-chip systems and algorithm design.

These enabling technologies will permit the development and delivery of the first integrated genetic and protein biomarker tests, applied here to Hepatitis C disease for: (i) making the decision to treat; (ii) selection of therapy; (iii) response-guided monitoring; and (iv) clinical research practices.

Hepatatis-C is a global public health problem with over 150 million people infected worldwide, representing a 15 billion Euro/year market. It is particularly prevalent in under-developed countries and treatments can be very costly.

One vision is to allow the physicians to make better treatment decisions (selecting the correct drug) and hence lower the total cost of treatment. In countries with many infected patients and limited healthcare budget this will provide an enormous improvement in quality of life for this patient group.

The algorithms developed by Qlucore will be based on classification techniques. They will also be available in future versions of Qlucore Omics Explorer and hence enable researchers and physicians in other areas to benefit from the results.

Qlucore has recruited and increased its engineering capacity in order to fulfil its role in the PoC HCV consortium. This, combined with the recently announced grant to Qlucore from VINNOVA (Swedish Governmental Agency for Innovation Systems) is additional validation of the high value being placed on developments currently being undertaken by Qlucore.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Revealing Human-growth Patterns in Transcriptomic Data
Understanding how children grow is key to understanding many childhood diseases and conditions, particularly those affecting growth.
Monday, May 19, 2014
Fighting to Reduce Dependence on Chemical Fungicides
The research is focused on how plants defend themselves against oomycetes and fungi.
Wednesday, February 19, 2014
Qlucore, Nebion Collaborate
Partnership aims to address complementary use cases.
Friday, February 07, 2014
Using Qlucore Omics Explorer for Interpreting Leukemia Proteomics Data
Qlucore software has speeded up the process and enabled discovery for leukemia researcher Steven Kornblau.
Monday, November 18, 2013
New Research Aims to Stop ‘Blood Doping' During Cycling and Other Competitive Sports
As cyclists take to the roads of Surrey, England, the subject of blood doping raises its head once again.
Thursday, August 01, 2013
How it Works: Advanced Data Analysis Using Visualisation
Visualisation is a powerful tool for those working in molecular biology, here Qlucore offers a five-step method to ensure repeatable and significant results.
Monday, June 24, 2013
Qlucore Receives R&D Funding
VINNOVA Grant will speed the interactivity and visual feedback of Next Generation Sequencing (NGS) data analysis for scientists.
Monday, April 29, 2013
Researchers Develop Animal Free Methods for Testing Chemical Compounds for Allergens
EU-funded research project developing in vitro (‘out of body’) test strategies to reduce or replace animal testing use gene expression analysis software.
Monday, April 08, 2013
Qlucore Targets Academic and Commercial Biotech, Life Science Markets with Novo Newton Scientific Ltd
New alliance increases Qlucore's sales and marketing presence in Ireland, Spain, Italy and South Africa.
Thursday, January 24, 2013
Visualising Complex Data Results from 100,000 Cancer Patients
For decades, biomedical scientists have tried to develop a diagnostic tool for the early stages of cancer.
Wednesday, December 12, 2012
New Biomarkers Could Offer Vital Clues for Cancer Research
European funding for cancer research has led to some interesting results in recent years, says Carl-Johan Ivarsson, CEO at Qlucore.
Friday, May 04, 2012
Unlocking the Secrets of Complex Genetic Data
A new approach to data analysis is helping researchers at Cincinnati Children's Hospital Medical Center to unravel the mysteries of human disease, says Carl-Johan Ivarsson, President of Qlucore.
Monday, March 19, 2012
New Research Techniques Could Help to Eliminate the Need for Animal Testing
Carl-Johan Ivarsson, Qlucore, comments on the reducing necessity for animal models in today’s drug development industry, as research moves more towards in vitro analysis.
Monday, March 19, 2012
NHS Urged to Prepare for ‘Genetic Revolution’
The ability to bring biologists into the data analysis phase will be key to achieving this important goal.
Monday, November 21, 2011
Qlucore to Expand its Marketing Efforts with New High-profile Appointment to its Board
New appointment coincides with the injection of new capital to increase market activities of its data analysis tool
Wednesday, November 25, 2009
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!